Thalia Therapeutics
Raised £2.8M
UK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeutics — Thalia Therapeutics, a British BioTech company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, has announced the acquisition of Sanmirna Therapeutics, alongside a €3.1 million (£2.75 million) raise. The round was supported by new and existing investors, including Premier Miton. The deal brings miRisten, a clinical-stage microRNA therapeutic candidate for Acute Myeloid […] The post UK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeutics appeared first on EU-Startups .
Get matched to investors deploying now.
Sign up to SeedPilot, complete your assessment, and we'll match you to the right UK investors.